fiboflapon (GSK 2190915) / BMS, GSK - LARVOL DELTA

Chemical burn wounds as a risk factor for gastric cancer: in-silico analyses-experimental research. (PubMed, Ann Med Surg (Lond)) - "Additionally, the current study presented five drugs, including Urokinase, Tenecteplase, DG031, AM103, and Fiboflapon, which can have predicted effects on gastric cancer following chemical burns. According to current in-silicon analyses, ALOX5AP and SERPINB2 are linked genetic keys between gastric chemical burn and cancer. Considering that burn is an environmental factor that leads to the upregulation of the two genes thus, the chemical burn can be related to the incidence of gastric cancer."

Journal • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Thermal Injury

Comprehensive analysis reveals potential hub genes and therapeutic drugs in an acquired lymphedema model. (PubMed, Gland Surg) - "Moreover, we identified the top 10 significant genes in the PPI networks and identified one extant drug, fiboflapon, that targets the ALOX5AP gene. We ultimately identified 10 hub genes, molecular mechanisms, and one extant drug related to acquired lymphedema. The findings identified targets and a potential drug for further research on acquired lymphedema."

Journal • Breast Cancer • Inflammation • Oncology • Solid Tumor

[VIRTUAL] Differential effects of pharmacological leukotriene pathway modulators in a human lung tissue explant model (ERS 2020) - "The fMLP-induced LTB4-production was effectively blocked by the FLAP inhibitors AZ13581258 (IC50=39 nM) and GSK2190915 (18 nM), whereas the CysLTR1 antagonist montelukast had no effect on leukotriene production. The glucocorticoid receptor agonist budesonide also had no effect, indicating the leukotriene pathway is largely insensitive to treatment by steroids. Pathway analysis based on gene expression profiles is ongoing. The ex vivo lung explant model shows promise as a translational model system enabling differentiation between leukotriene pathway modulators."

Asthma • Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor

GSK2190915A - Bioavailability Study (clinicaltrials.gov) - P1; N=67; Completed; Sponsor: GlaxoSmithKline

New P1 trial • Asthma • Biosimilar • Immunology

The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen (ERS 2011) - P2, N=19; NCT00812773; GSK2190915 had a significant effect on EAR, treatment difference from PBO for 10mg was 0.212 L & for 50mg was 0.409 L for minimum FEV1 in 2 hours after allergen inhalation; Safety & tolerability were good

P2 data • Asthma

GSK2190915 Neutrophilic Asthma Study (clinicaltrials.gov) - P2; N=14; Completed; Sponsor: GlaxoSmithKline

Clinical • New P2 trial

GSK2190915 Neutrophilic Asthma Study (clinicaltrials.gov) - P2; N=14; Completed; Sponsor: GlaxoSmithKline; Active, not recruiting ➔ Completed

Clinical • Trial completion